scholarly journals Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

2013 ◽  
Vol 5 (4) ◽  
pp. 210-233 ◽  
Author(s):  
Chau-Ching Liu ◽  
Amy H. Kao ◽  
Susan Manzi ◽  
Joseph M. Ahearn
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
The Future

Systemic lupus erythematosus—management

2013 ◽  
pp. 938-947
Author(s):  
Ida Dzifa Dey ◽  
David Isenberg
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
General Management ◽  
Autoimmune Rheumatic Disease ◽  
The Future

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with varied presentation and a disease course characterized by remission and flares. Over the last 50 years the prognosis of SLE has improved considerably. The introductions of corticosteroids and later of cytotoxic drugs, dialysis, and renal transplantation were the major contributors to this improvement. Nevertheless, the treatment and general management of lupus continues to present a challenge. While lupus may, for some patients, represent a relatively mild set of problems, many others require large doses of immunosuppressive drugs, which carry long-term concerns about side effects. New immunotherapeutic drugs, with actions more closely targeted to the immune cells and molecules involved in the pathogenesis of SLE, are being introduced and the future looks promising. The role of early atherosclerosis and cardiovascular disease as a cause of death in patients with SLE is increasingly recognized and will present further challenges in the future.

Systemic lupus erythematosus—management

2016 ◽  
Author(s):  
Ida Dzifa Dey ◽  
David Isenberg
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
General Management ◽  
Autoimmune Rheumatic Disease ◽  
The Future ◽  
Early Atherosclerosis

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with varied presentation and a disease course characterized by remission and flares. Over the last 50 years the prognosis of SLE has improved considerably. The introductions of corticosteroids and later of cytotoxic drugs, dialysis, and renal transplantation were the major contributors to this improvement. Nevertheless, the treatment and general management of lupus continues to present a challenge. While lupus may, for some patients, represent a relatively mild set of problems, many others require large doses of immunosuppressive drugs, which carry long-term concerns about side effects. New immunotherapeutic drugs, with actions more closely targeted to the immune cells and molecules involved in the pathogenesis of SLE, are being introduced and the future looks promising. The role of early atherosclerosis and cardiovascular disease as a cause of death in patients with SLE is increasingly recognized and will present further challenges in the future.

Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study

Lupus ◽  
2015 ◽  
Vol 25 (1) ◽  
pp. 61-66 ◽  
Author(s):  
D Castillo-Martínez ◽  
E Marroquín-Fabián ◽  
A C Lozada-Navarro ◽  
M Mora-Ramírez ◽  
M Juárez ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pulmonary Hypertension ◽  
Uric Acid ◽  
Future Development ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Follow Up Study ◽  
The Future

New therapies for systemic lupus erythematosus: has the future arrived?

2006 ◽  
Vol 1 (2) ◽  
pp. 235-247 ◽  
Author(s):  
Arvind Kaul ◽  
David D'Cruz ◽  
Graham RV Hughes
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
New Therapies ◽  
The Future

The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future

2019 ◽  
Vol 26 (5) ◽  
pp. 360-368 ◽  
Author(s):  
Isabelle Ayoub ◽  
Clarissa Cassol ◽  
Salem Almaani ◽  
Brad Rovin ◽  
Samir V. Parikh
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Kidney Biopsy ◽  
Systemic Lupus ◽  
The Past ◽  
The Future

Systemic lupus erythematosus—management

2013 ◽  
pp. 938-947
Author(s):  
Ida Dzifa Dey ◽  
David Isenberg
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
General Management ◽  
Autoimmune Rheumatic Disease ◽  
The Future

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with varied presentation and a disease course characterized by remission and flares. Over the last 50 years the prognosis of SLE has improved considerably. The introductions of corticosteroids and later of cytotoxic drugs, dialysis, and renal transplantation were the major contributors to this improvement. Nevertheless, the treatment and general management of lupus continues to present a challenge. While lupus may, for some patients, represent a relatively mild set of problems, many others require large doses of immunosuppressive drugs, which carry long-term concerns about side effects. New immunotherapeutic drugs, with actions more closely targeted to the immune cells and molecules involved in the pathogenesis of SLE, are being introduced and the future looks promising. The role of early atherosclerosis and cardiovascular disease as a cause of death in patients with SLE is increasingly recognized and will present further challenges in the future.

Systemic lupus erythematosus—management

2013 ◽  
Author(s):  
Ida Dzifa Dey ◽  
David Isenberg
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
General Management ◽  
Autoimmune Rheumatic Disease ◽  
The Future ◽  
Early Atherosclerosis

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with varied presentation and a disease course characterized by remission and flares. Over the last 50 years, the prognosis of SLE has improved considerably. The introductions of corticosteroids and later of cytotoxic drugs, dialysis, and renal transplantation were the major contributors to this improvement. Nevertheless, the treatment and general management of lupus continues to present a challenge. While lupus may, for some patients, represent a relatively mild set of problems, many others require large doses of immunosuppressive drugs, which carry long-term concerns about side effects. New immunotherapeutic drugs, with actions more closely targeted to the immune cells and molecules involved in the pathogenesis of SLE, are being introduced and the future looks promising. The role of early atherosclerosis and cardiovascular disease as a cause of death in patients with SLE is increasingly recognized and will present further challenges in the future.

scholarly journals The Wolf’(s)-B(r)ain- The Past, Present, Future of CNS Lupus

2019 ◽  
Vol 16 (3) ◽  
pp. 6-14
Author(s):  
Murali Suhas ◽  
Srikanteshwara Parveen-Kumar
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Review Article ◽  
Future Research ◽  
Systemic Lupus ◽  
Research Directions ◽  
Cns Lupus ◽  
The Past ◽  
The Future ◽  
Future Research Directions

Systemic Lupus Erythematosus is a long-studied condition with protean manifestations, yet, with so much known about the pathogenesis and treatment aspects still in the dark. In this review article, we try to sum up all the knowledge we have till date, the practice essentials used to date and the future research directions, all of which ultimately lead to a better understanding of the disease and its management.

Sign in / Sign up

Export Citation Format

Share Document